Introduction
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA) largely used as an immunosuppressive drug to prevent acute rejection following solid organ transplantation , . MMF is also used in the prophylaxis and treatment of acute and chronic [1 2 ] graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HCT), or to improve the engraftment in nonmyeloablative and reduced-intensity conditioning HCT . [3 -15 ] On the one hand, the therapeutic drug monitoring (TDM) of MMF when used in solid organ transplantation is debated but could [16 ] be recommended as it has been demonstrated that the control of exposure to MPA helps to maximize its immunosuppressive effects . [2 ] More precisely, an area under the twelve-hour concentration-time curve (AUC ) of MPA between 30 and 60 mg.h/L is recommended [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] for at least the first six months post-renal or heart transplantation, when MMF is used in combination with cyclosporine and steroids , [1 2 ] . Bayesian estimators, based on pharmacokinetic models and using sparse individual data have been developed to estimate the dose providing a target AUC value for each patient , . Some of these Bayesian estimators, derived from PK models built from large [17 18 ] populations of transplanted patients, have been successfully used in a prospective concentration-controlled clinical trial using a limited " " sampling strategy (20 min, 1 h, 3 h) . These tools are also routinely used by transplantation centres via an expert system available on a [19 ] website ( ) . https://pharmaco.chu-limoges.fr/abis.htm [20 ] On the other hand, very little information is available about the TDM of MMF when used in HCT patients. The previous pharmacokinetic studies have reported a wide interpatient variability with a mean total MPA exposure below that recommended in solid organ transplantation , , , . Interestingly, mean dose-normalized MPA AUC values observed in HCT patients are almost 50 [3 5 7 -9 14 ] % lower than in renal transplant patients , . These observations advocate for MMF administration instead of as in solid organ [7 14 ] tid bid transplantation , . This also implies dose adjustments in HCT patients, but also strongly suggests that the pharmacokinetic [10 21 ] parameters and their associated tools developed for solid organ transplant recipients would not be suitable for HCT. Furthermore, a recent study underlines the interest of TDM of MPA in terms of reduction of inter-patient variability . [22 ] This pilot study aimed at modelling MPA pharmacokinetics and developing maximum Bayesian estimators (MAP-BEs) a posteriori for the estimation of MPA exposure in reduced-intensity HCT patients given MMF as part of their immunosuppressive regimen.
Patients and methods

Patients
Fourteen patients were enrolled in the study. The inclusion criteria were: patient likely to receive a reduced-intensity HCT as determined by the French Haematological Society, age ranging from 18 to 70 years, signing of informed consent, absence of intercurrent disease which could interfere with the short term survival of the patient or graft. Non inclusion criteria were hypersensitivity to MPA, patients who present contraindications to MPA, patients with severe gastro-intestinal disorders, drug addictions or psychiatric disorders which mean they might not be able to understand the protocol. This clinical trial was designed in accordance with the legal requirements and approved by a local ethics committee.
The reduced-intensity regimen was a combination of fludarabine and melphalan (in 8 cases), with total body irradiation (2 Gy in 2 cases) or with both cyclophosphamide and total body irradiation (2 Gy in 4 cases. The immunosuppressive regimen for the prevention of GVHD was a combination of cyclosporine administered orally twice daily (start dose: 5mg/kg/day; targeted through concentration: 250 ng/mL) and MMF administered at the dose of 15 mg/kg three times daily. However, because of the galenic formulation of MMF (tablets of 500 and capsules of 250 mg), the actual dose administered was rounded off 1g of MMF . The two treatments were started 3 days before tid the HCT.
The supportive care medication was as previously described . Briefly, it consisted in bacterial prophylaxis using [23 ] phenoxymethylpenicilline (3 MU/day) or spiramycine (3 MU/day). Valacyclovir p.o. was administered to prevent CMV prophylaxis: 500 mg twice daily if donor and recipient was serologically CMV negative; 1g 3 daily when donor and/or recipient was CMV positive. Oral × itraconazole (400 mg daily) or posaconazole (200 mg tid) were administered if fungal prophylaxis was needed.
Pharmacokinetic profiles
Three profiles were performed during the first month of HCT: one at the beginning of the treatment three days before the HCT and one 7 ( 1) days later, i.e. 4 days after HCT. Finally a PK profile was collected after the morning on day 30 ( 5) after the first PK profile. The ± ± two first PK profiles correspond with a two 8-hour PK profiles performed consecutively at the initiation of the MMF treatment. The sequence of sampling was: pre-dose, 20, 40 and 60 minutes after the first administration in the morning, thereafter 2, 4, 6 and 8 hours.
Then samplings were performed at 20, 40 and 60 minutes and 2, 4, 6 and 8 hours after the administration of the second dose of MMF.
Finally, the last PK profile corresponds with a 8-hour PK profile collected after the morning on day 30.
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Assay
The measurement of total MPA was performed using an HPLC method with UV detection derived from . Briefly, a mixture of 1 [24 ] mL whole blood and 4 g of internal standard (thiopental) were acidified with chlorhydric acid and extracted with 4 mL of μ dichloromethane. The organic fraction was then evaporated to dryness under a stream of nitrogen. The drug residue was reconstituted with the elution solvent (NaH PO buffer/acetonitrile (58/42 v/v) at pH 2.7). Thirty L of sample were injected into the HPLC system with a 2 4 = μ X-Terra column and precolumn (Waters, Saint Quentin en Yvelines, France) and with a UV detection at 254 nm. This method exhibits a lower limit of quantification of 0.1 mg/L and a coefficient of variation of 6.0 for interday accuracy at the 1 mg/L concentration.
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PK modelling
The pharmacokinetic profiles were described by one-compartment open models with first-order elimination combined with a Gamma model of absorption with either two or three parallel absorption routes. These PK models were previously published to describe PK profiles of MPA in renal transplant patients , and in patients suffering from lupus . Briefly, in these models, the absorption rate [17 18 ] [25 ] at time t was described by a sum of Gamma distributions:
where F is the bioavailability coefficient, D is the administered dose, fi represents the absorption rate through the i-th route (normalized by FD), is the Gamma function, (a , b ) the parameters of the Gamma distributions, r is the fraction of drug absorbed
through the i-th route. No independent determination of the bioavailability factor F was possible, since no intravenous data was available for these patients.
The disposition kinetics, i. e. the impulse response I(t) of the system, was described by a one-compartment model, according to the The convolution product of the absorption rate and disposition function was computed analytically as previously described , : [26 27 ] Where C is the concentration at time t, C the trough concentration, a and b the parameters of the Gamma distributions, r is the 0 i i i fraction of drug absorbed through the i-th route, and P denotes the incomplete Gamma function:
Where is the exponent of the incomplete Gamma function, is the independent variable (argument of the incomplete Gamma n x function) and z is the integration variable.
Bayesian estimation of individual pharmacokinetic parameters
The individual parameters (vector ) for each patient were determined by minimizing the following objective function: 
(detV) was used as a measure of the precision of the determined parameters with which parameters were determined (the lower the determinant, the higher the precision).
Population pharmacokinetics
The population pharmacokinetic parameters for were determined by the iterative two-stage (ITS) method , , using our own [28 29 ] program. At each iteration of the method, the following two steps were performed:
Individual estimates and V (k 1..N) for the N patients were obtained by Bayesian estimation as described above
New estimates of the population mean vector and population variance-covariance matrix were computed by:
The interindividual variability of the pharmacokinetic parameters was assessed by computing the medians and 50 dispersion factors % (DF50). DF50 is defined as (Q75 -Q25)/1.32, whereQ75 and Q25 are the 25 and 75 quartiles, respectively, and 1.32 represents the % % width of the interval covering 50 of the observations in the case of a normal distribution. DF50 is equal to the standard deviation for % normally distributed parameters and provides a reasonable estimate of the dispersion of a non-Gaussian distribution . [26 ] The calibration experiments showed that the standard deviation Si of a measured concentration Ci could be expressed as a polynomial function Si 0.02 0.033 Ci, where Ci and Si are in mg/L. Si was used as concentration weighting factor.
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For each PK profile, the two PK model were applied and the best one was selected based on the lowest Akaike Information Criterion [ , calculated as follows : 30 ] Where is the value of the objective function at minimum, and p the number of parameters in the model. [ 17 18 ] post-dose were tested for Bayesian forecasting. Indeed, such a sampling scheme seemed to be a good compromise between the precision of parameter estimates and a possible implementation in clinical practice.
The D-optimality criterion applied to Bayesian estimation was used to compare these candidate LSS as follows: [30 ] For given sampling times t , t , the corresponding concentrations C , C , were computed by , using the population mean
eq. (4) vector .
The variance-covariance matrix was then computed with . The sampling times giving the lowest value of det were selected as eq. (7) V the best sampling times. In a second step, a data-splitting procedure was performed to validate these MAP-BEs, in accordance with previous reports , . [32 33 ] For each period, patients were randomly divided into subsets containing approximately 80 of the patients. To test the robustness of the % model, new population parameters were obtained in each 80 subset and were then compared with those resulting from the entire " % "
population. To test the predictive performance of the MAP-BEs, the parameter estimates from each of the subsets were used to estimate the PK parameters and the AUCs of the remaining 20 patients. The predicted AUCs were compared with those obtained using the linear % trapezoidal rule by means of the mean bias and RMSE.
Results
The characteristics of the patients are summarized in . All PK profiles could be achieved except in two cases: one on D30 due Table 1 to missing data and one on D7 because the MMF treatment was administered intravenously after the development of an oral mucositis.
The MMF dose was of 1000 mg for all the patients for the first PK profile. On D7, the MMF dose was of 1000 mg except in three tid tid patients (two at 750 mg and 1 at 500 mg ). The reducing of these doses was maintained for the last PK period (D30) and extended to tid tid one additional patient (750 mg ). On D30, the MMF dose was increased for one patient (1500 mg ). tid tid
The observed concentration-time profiles obtained before transplantation and on D7 and D30 are presented in . Whatever the figure 1 period, these individual profiles were satisfactorily described using a one-compartment model with either a double or a triple gamma absorption. Some typical examples illustrating the good-of-fit are given on . The performance of the models are depicted in table x figure 2 (published as only online supplementary material). Interestingly, for each parameter of the models, the precision of the estimation gave satisfactory results (from 5.2 to 32.6 , depending on both period or PK model). Also, the medians were very close to the means, the DF50 % values very close to the standard deviations and the Kolmogorov-Smirnov test did not find significant deviations from the normal distribution, as required. Thus, population PK parameters of the two models were used as priors for Bayesian estimation. The Akaike criterion was pertinent in discriminating which model best fitted each patient s data. A typical example of the difference in data modelling ' using a double gamma or a triple gamma model and the corresponding Akaike criterion values is presented in .
With respect to both the AUC estimation performance and the D-optimality criterion, the combination of sampling times at 20min, 0 8 h -90min and 240min post-dose was found to be the best compromise when considering all the pre-and post-transplantation periods. Figure 3 gives four typical examples of MPA PK profiles estimated using Bayesian fitting. The predictive performance of the different MAP-BEs is summarized in . For each period, mean bias between calculated and trapezoidal AUC was less than 2.5 and the percentage of table 2
patients with a bias greater than 20 was less than 16 . Precisely, on D7, 2 out of 12 patients were estimated with a bias of 23 and 28
, respectively. These 2 last cases are presented in .
The MAP-BEs were then validated using a data-splitting strategy. After randomly dividing the patients of the full dataset into subsets containing approximately 20 of the patients, the individual PK parameters of each patient in the remaining 80 subset was obtained
using the final model developed from the whole dataset. In this first step the mean parameter estimates obtained in each 80 subset were
not statistically different from those resulting from the entire dataset, which showed the robustness of the model. The mean SD of the ± parameter estimates from each 80 subset were then used to predict the individual AUC values in the remaining 20 subset . In this
second step, the mean bias between individual AUC values estimated using the 20min-90min-240min sampling schedule and the trapezoidal rule was less than 9 . Whatever the period, less than 16 of the AUC were estimated with a relative difference of more than % % 20 (2 out of 14 patients on day 7 and 2 out of 14 patients on the 1 administration).
Discussion
We report the development of pharmacokinetic models that adequately describe full pharmacokinetic profiles of MPA obtained in patients receiving MMF three times daily in the context of a reduced-intensity HCT. We also developed Bayesian estimators allowing the determination of the MPA AUC on the basis of a three-point limited sampling strategy within the first 4 hours post-dose.
0-8h
Patients enrolled in the present study provided full MPA PK profiles before transplantation, then on D4 and D27 post-transplantation.
When looking at the raw data, we observed that the patients usually exhibited profiles with more than one peak. For this reason, we decided to develop a model able to describe a secondary peak, similar to that previously reported for solid organ transplantation , .
Due to the complexity of some profiles, a model allowing the description of an additional peak was also constructed. As this leads to an increase in the number of independent estimated parameters, we proposed the use of the Akaike criterion (AIC) to prevent overfitting and to determine the model that best explains each individual data with a minimum of PK parameters.
Indeed, AIC reflects not only the goodness of fit, but also includes a penalty which is an increasing function of the number of estimated parameters. For each patient, Bayesian fitting was thus automatically performed using the two PK models, and only the results corresponding to the lowest AIC value were considered and reported. Of note, such a strategy is routinely performed on the ISBA website ( ) where PK modelling is performed systematically using a one-and a two-gamma absorption https://pharmaco.chu-limoges.fr/abis.htm model, and the AIC criterion is used to choose which results will be used for dose adjustment of MMF when used in solid organ transplantation.
Only a few pharmacokinetic studies have been published describing the MPA PK parameters or exposures when MMF is administered to HCT patients in prevention of GVHD, especially after reduced-intensity regimen , , , . These studies have reported that the [7 8 12 34 ] mean exposure to MPA (in its total or unbound form) is significantly lower than that observed in solid organ transplantation. The causes of this phenomenon are still controversial. However, to the best of our knowledge, only two MPA PK studies have been performed in HCT patients with the aim of building a tool for improving the therapeutic drug monitoring of MMF , . Using a noncompartmental [35 36 ] approach, Ng . have developed different equations derived from multilinear regression models allowing the estimation of total or et al unbound MPA AUC in HCT patients given MMF orally or intravenously. In the second study, Huang aimed at developing a PK et al model able to estimate unbound MPA concentrations from unbound MPA concentrations. However, using their multilinear regression equation failed to provide a satisfactory prediction for clinical assessment. In the present study, we developed Bayesian estimators able to accurately estimate AUC as well as the relevant pharmacokinetic parameters or exposure indices to MPA using three sampling times. As compared to algorithms using multilinear regression models, the combination of the patient s information and the PK model leads to an ' accurate estimation of unusual pharmacokinetic profiles and is less sensitive to imprecision in sampling time.
" "
A data-splitting strategy was performed here to validate both the PK models and MAPB-BEs. This approach was recommended by the
U.S. Department of Health and Human Services of the U.S. Food and Drug Administration (FDA)
. Precisely, although external [37 ] validation is the gold standard for testing the accuracy of a population model for predictive purposes in clinical practice, this method is
hardly usable when the population studied is too small to be divided into a building and a validation group. This was the case in the present study. In fact, the diminution of the building group s size leads to a decrease in the accuracy of the parameters and variability estimates.
'
However, an external validation of the developed MAP-BEs is required before they can either be proposed to the physicians in charge of HCT patients through the ISBA website, or used to conduct a concentration-controlled trial such as the one which recently showed the significant improvement for renal transplant patients using such a strategy and a couple of other on-going studies in liver [19 ] transplantation.
Conclusion
Currently mycophenolate mofetil is widely used in solid organ transplantation. Numerous pharmacokinetic studies and some " controlled-concentration trials have led, in the last few years, to a significant improvement of its monitoring in these patients. MMF is " also prescribed in HCT, but prescribed doses are still empirical as target exposure indices still have to be defined. In this study, we developed PK that satisfactory described MPA absorption profiles when given to HCT patients. Additionally, Bayesian estimators able to determine the AUC on the basis of a routinely usable limited sampling strategy. However, further studies are needed to validate these tools in independent groups of patients.
Figure 1
Observed concentration-time profiles of mycophenolic acid in patients given mycophenolate mofetil every 8 hours in non myeloablative haematopoietic cell transplantation. (a) before transplantation; (b) 4 days after the initiation of MMF treatment; (c) 27 days after the initiation of MMF treatment.
Figure 2
Individual mycophenolic acid plasma concentration versus time curves at different periods of the study fitted using the developed PK models. Myelodysplastic syndrome -refractory anemia with excess of blasts 1
Chronic myeloid leukemia 1
Acute myeloid leukemia (whatever the type) 7
Chronic lymphoblastic leukemia 1 agnogenic myeloid metaplasia 1 
